Drugs / Ganitumab
last change Feb 2025 re-read 2 minutes ago

Ganitumab

also known as AMG 479

Monoclonal antibody targets IGF1R via inhibition

Developed for
pancreatic adenocarcinoma · colorectal cancer · Ewing sarcoma · sarcoma · carcinoid tumor · lymphoma · metastatic malignant neoplasm · non-small cell lung carcinoma
+21 more · ovarian neoplasm · alveolar rhabdomyosarcoma · Askin tumor · bone marrow cancer · breast cancer · cancer · cancer of unknown primary site · desmoplastic small round cell tumor · embryonal rhabdomyosarcoma · extraskeletal Ewing sarcoma · female breast carcinoma · malignant pancreatic neoplasm · metastatic neoplasm · non-small cell squamous lung carcinoma · pancreatic ductal adenocarcinoma · pancreatic neuroendocrine tumor · peripheral primitive neuroectodermal tumor of bone · peripheral primitive neuroectodermal tumor of soft tissues · prostate cancer · small cell lung carcinoma · small intestine cancer
Investigated by
NantCell, Inc. · National Cancer Institute (NCI) · Amgen · NantBioScience, Inc. · Dana-Farber Cancer Institute · M.D. Anderson Cancer Center
+22 more · Novartis Pharmaceuticals · Translational Research in Oncology · 1 Million 4 Anna Foundation · Alan B. Slifka Foundation · Alliance for Clinical Trials in Oncology · Brigham and Women's Hospital · Carson Sarcoma Foundation · ChemoWarrior: the eli sidler foundation · H. Lee Moffitt Cancer Center and Research Institute · Jeffrey Clarke · Jonsson Comprehensive Cancer Center · Massachusetts General Hospital · NRG Oncology · Novartis · Pfizer · QuantumLeap Healthcare Collaborative · Radiation Therapy Oncology Group · Rutledge Cancer Foundation · Shadia Jalal · Takeda · Teaming up to Fight Childhood Cancer · i-ROK Foundation

Trials 28 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT01298401 Feb 2012 → Nov 2013 malignant pancreatic neoplasm Radiation Therapy Oncology Group Completed No outcome recorded
Phase 1 NCT01122199 May 2010 → Jan 2015 metastatic neoplasm Shadia Jalal Completed No outcome recorded
Phase 1 NCT01061788 Apr 2010 → Dec 2018 non-small cell lung carcinoma Jeffrey Clarke Completed No outcome recorded
Phase 1 NCT00974896 Dec 2006 → Sep 2010 cancer NantCell, Inc. Completed No outcome recorded
Phase 1 NCT00562380 Oct 2005 → Apr 2010 cancer of unknown primary site, lymphoma, prostate cancer, sarcoma +1 Amgen Completed No outcome recorded
Phase 1/29 trials
Phase 1/2 NCT03041701 Jul 2017 → Sep 2021 alveolar rhabdomyosarcoma, embryonal rhabdomyosarcoma National Cancer Institute (NCI) Terminated No outcome recorded
Phase 1/2 NCT01708161 Nov 2012 → Dec 2014 Novartis Pharmaceuticals Terminated No outcome recorded
Phase 1/2 NCT01479179 Nov 2012 → Nov 2015 breast cancer M.D. Anderson Cancer Center Withdrawn No outcome recorded
Phase 1/2 NCT01562899 Aug 2012 → Apr 2015 pancreatic adenocarcinoma Pfizer Terminated No outcome recorded
Phase 1/2 NCT01473303 Aug 2012 pancreatic ductal adenocarcinoma Alliance for Clinical Trials in Oncology Withdrawn No outcome recorded
Phase 1/2 NCT00807612 Jan 2009 → Aug 2010 non-small cell squamous lung carcinoma NantCell, Inc. Terminated No outcome recorded
Phase 1/2 NCT00791154 Dec 2008 → Feb 2010 small cell lung carcinoma NantCell, Inc. Terminated No outcome recorded
Phase 1/2 NCT00788957 Oct 2008 → Jul 2010 colon carcinoma, rectal cancer NantBioScience, Inc. Completed No outcome recorded
Phase 1/2 NCT00630552 Jun 2007 → Jan 2010 pancreatic adenocarcinoma NantCell, Inc. Completed No outcome recorded
Phase 210 trials
Phase 2 NCT04129151 Dec 2019 → Dec 2022 Ewing sarcoma Dana-Farber Cancer Institute Terminated No outcome recorded
Phase 2 NCT01318642 May → Nov 2012 pancreatic adenocarcinoma NantBioScience, Inc. Terminated No outcome recorded
Phase 2 NCT01327612 Mar 2011 → Feb 2020 carcinoid tumor, colorectal cancer, lymphoma, metastatic malignant neoplasm +2 Amgen Completed No outcome recorded
Phase 2 NCT01042379 Mar 2010 → Dec 2030 expected HER2 positive breast carcinoma, angiosarcoma, female breast carcinoma, hormone receptor-positive breast cancer +1 QuantumLeap Healthcare Collaborative Recruiting No outcome recorded
Phase 2 NCT01024387 Mar 2010 → Jan 2016 carcinoid tumor, pancreatic neuroendocrine tumor Dana-Farber Cancer Institute Completed No outcome recorded
Phase 2 NCT00891930 May 2009 → Jul 2013 colorectal cancer NantBioScience, Inc. Completed No outcome recorded
Phase 2 NCT00813605 Mar 2009 → Jan 2011 colorectal cancer NantCell, Inc. Completed No outcome recorded
Phase 2 NCT00719212 Jan 2009 → May 2013 ovarian neoplasm Translational Research in Oncology Completed No outcome recorded
Phase 2 NCT00718523 Jan 2009 → Sep 2013 ovarian neoplasm Translational Research in Oncology Terminated No outcome recorded
Phase 2 NCT00563680 Oct 2007 → Aug 2009 Askin tumor, desmoplastic small round cell tumor, extraskeletal Ewing sarcoma NantCell, Inc. Completed No outcome recorded
Phase 32 trials
Phase 3 NCT02306161 Dec 2014 → Mar 2021 overdue Ewing sarcoma, bone marrow cancer, metastatic malignant neoplasm, peripheral primitive neuroectodermal tumor of bone +1 National Cancer Institute (NCI) Active not recruiting No outcome recorded
Phase 3 NCT01231347 Apr 2011 → Dec 2012 malignant endocrine neoplasm, metastatic carcinoma in the bone, pancreatic adenocarcinoma NantCell, Inc. Completed No outcome recorded
Phase not applicable1 trial
NCT04199026 Feb 2025 → Dec 2028 expected sarcoma M.D. Anderson Cancer Center Recruiting No outcome recorded
Phase not stated1 trial
NCT03029481 Ewing sarcoma Jonsson Comprehensive Cancer Center No longer available No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT00819169 Background Jan 2009 → Aug 2011 colorectal cancer, malignant pancreatic neoplasm, metastatic malignant neoplasm, non-small cell lung carcinoma +2 NantCell, Inc. Terminated No outcome recorded
Phase 21 trial
Phase 2 NCT00626106 Comparator Mar 2008 → May 2010 female breast carcinoma, metastatic malignant neoplasm NantCell, Inc. Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 30 sources stand behind the page.

FieldValueCited text
Known as ganitumab “for AMG479 (ganitumab) and RAD001 (everolimus).” NCT01122199
12

NCT02306161

NCT00788957

NCT03041701

NCT00562380

NCT03029481

NCT01327612

NCT04199026

NCT04129151

NCT01042379

NCT01298401

NCT00891930

NCT01473303

Known as AMG 479 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01024387
17

NCT00974896

NCT01318642

NCT00563680

NCT00819169

NCT00626106

NCT00719212

NCT01061788

NCT01708161

NCT00718523

NCT01122199

NCT00630552

NCT01562899

NCT01231347

NCT00813605

NCT00791154

NCT01479179

NCT00807612

Action Inhibit “AMG 479 inhibits the binding of both IGF-1 and IGF-2 to IGF-1R, thus inhibiting ligand-dependent receptor activation.” NCT00563680
Modality Monoclonal antibody “fully human monoclonal antibody (IgG1)” NCT00563680
Route Intravenous “Arm A: AMG 479 12 mg/kg IV Q2W + Endocrine Therapy” NCT00626106
Target IGF1R “targeted against insulin-like growth factor receptor type 1 (IGF-1R)” NCT00630552